Navigation Links
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Date:8/19/2007

SEATTLE, Aug. 17 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced publication of results from a Phase 1 study of NEUVENGE, an investigational active cellular immunotherapy, in the August 20 issue of the Journal of Clinical Oncology. The article highlights the safety profile, immune response and clinical activity of NEUVENGE in women with HER2/neu-positive breast cancer who have failed standard therapy.

"In addition to demonstrating that NEUVENGE was safe and well tolerated, the T-cell responses seen in these patients and the prolonged disease stabilization in the absence of other anti-cancer therapies in many patients is promising," said John W. Park, M.D., associate clinical professor of medicine and neurosurgery at the University of California, San Francisco and lead author of the publication. "These observations are encouraging and are suggestive of the clinical benefit of NEUVENGE, particularly in light of the aggressive cancer seen in these patients who had progressed while on standard therapy. The findings warrant additional studies of NEUVENGE for the many women with advanced breast cancer who have exhausted many of their treatment options."

Study Design

The Phase 1 study (D2000-2) was conducted to evaluate the safety and immunologic activity of NEUVENGE in patients with HER2-overexpressing metastatic breast cancer who had failed standard therapy, including prior treatment with chemotherapy and trastuzumab. All patients had experienced disease progression while on standard therapy. There were 19 patients enrolled in the study with 18 patients receiving treatment with NEUVENGE. Patients underwent three infusions of NEUVENGE at Weeks 0, 2, and 4 following randomizati
'/>"/>

SOURCE Dendreon Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Presentation of Data at American Urological Association Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... MELBOURNE, Australia , Sept. 18, 2014 /PRNewswire/ ... the appointments of Dr. Ashraf Hanna , M.D., ... to its Board of Directors. Dr. Hanna is the ... Genentech and Chief Financial Officer for the Genentech Foundation, ... and Global Head of Business Development and Licensing for ...
(Date:9/18/2014)... Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage ... pain, announced today that it has appointed Mr. ... Director of Clinical Development. During his extensive ... led successful global clinical operations teams, in the US ... clinical development of numerous therapeutics and diagnostics across a ...
(Date:9/18/2014)... /CNW/ - A new expert panel report, Improving Medicines ... released today by the Council of Canadian Academies, addresses ... children. Each year about half of Canada,s ... prescription drug. Much of this prescribing is done off-label ... potential health risks. Children have historically been ...
Breaking Medicine Technology:Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3
... publication in prominent peer-reviewed journal highlights,findings of ... infection, EVANSTON, Ill., March 17 ... using a,rapid molecular diagnostic test is effective ... published in the Annals of Internal Medicine,by ...
... on Track to Initiate Phase 2b in Second Quarter ... - Conference Call Tomorrow at 8:00 a.m. ... Ardea Biosciences, Inc.,(Nasdaq: RDEA ) today announced positive ... RDEA806, its novel,investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in,patients ...
Cached Medicine Technology:Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention 2Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention 3Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 2Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 3Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 4
(Date:9/18/2014)... By Randy Dotinga ... -- Women who have the largest number of post-traumatic stress ... an addiction to food, a new study suggests. ... women overeating or becoming addicted to food. And it,s also ... experiencing trauma, PTSD, or both. Still, the research ...
(Date:9/18/2014)... 18, 2014 How much is a ... of the factors contributing to the obesity epidemic in ... single serving and how to manage portion size during ... Oct. 3 at Humility House, 755 Ohltown Road, Austintown. ... lead the informational discussion and answer questions from 12:30 ...
(Date:9/18/2014)... Texas Physical Therapy Specialists (TexPTS) is proud to ... Association (HPA) Friends and Family Golf tournament on ... tournament, which will take place at TopGolf from 9 ... through three golf challenges, “Top Scramble”, “Top Score”, and ... provided at the event and there will be open ...
(Date:9/18/2014)... Eye doctors have long known that staring ... basal tear film in the eyes to lose water and ... that staring at a computer screen can also alter the ... about computers, the tear film and dry eye for years ... (*Gray, Sarah, “Staring at Screen is Altering Your Tears, Study ...
(Date:9/18/2014)... 18, 2014 Members of United ... participating network dentists at UnitedConcordia.com, thanks to a ... company. , "Members can book an appointment with ... button located on the Find a Dentist page ... of network operations at United Concordia. "We are ...
Breaking Medicine News(10 mins):Health News:PTSD Link to Food Addiction Seen in Report 2Health News:PTSD Link to Food Addiction Seen in Report 3Health News:HMHP Workshop Addresses Portion Control 2Health News:Texas Physical Therapy Specialists Sponsoring HPA Friends & Family Golf Tournament 2Health News:New Study Confirms that Staring at a Computer Screen Alters Tear Film Content and Causes Dry Eye 2Health News:New Study Confirms that Staring at a Computer Screen Alters Tear Film Content and Causes Dry Eye 3Health News:United Concordia Offers Real-time Online Scheduling for their Members, Through LocalMed 2Health News:United Concordia Offers Real-time Online Scheduling for their Members, Through LocalMed 3
... , , LEXINGTON, Ky., Sept. ... stopping in Kentucky throughout the week of September 8 - 11 ... access information on programs that provide prescription medicines for free or ... -- one of the worst rates in the nation -- the ...
... BATESVILLE, Ind., Sept. 4 Hill-Rom Holdings, Inc. (NYSE: ... $0.1025 per share. This dividend was declared by Hill-Rom,s Board of ... to shareholders of record as of September 16, 2009. , , ... is a leading worldwide manufacturer and provider of medical technologies and related ...
... , , , DETROIT, Sept. ... Daniel J. Loepp made the following statement in conjunction with the ... with a serious illness. , , Blue Cross ... to jointly announce Mr. Harwell,s retirement as Blue Cross,s health and ...
... , , , ... Dk hybrid contact lens manufacturer, recently introduced a new ... revolutionary contact lens that takes advantage of the best ... centration, stability, and all-day comfort. The patent-pending design is ...
... , NEW HAVEN, Conn., Sept. 4 ... development and commercialization of novel antibiotics for the treatment of ... has joined the company as Chief Business Officer. In his ... activities. , , Mr. Kassberg, age 49, ...
... , NEW YORK, Sept. 4 Delcath Systems, ... its proprietary treatment method for primary and metastatic cancers to the ... make a presentation to investors at the Rodman & Renshaw 11th ... Time in New York. Mr. Hobbs will review the Company,s business ...
Cached Medicine News:Health News:Partnership for Prescription Assistance Prepared to Help Kentucky Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Kentucky Workers Hurt by Recession 3Health News:SynergEyes, Inc. Expands Launch of New Hybrid Contact Lens Design for Keratoconus Patients 2Health News:Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer 2
... hands play an important part in our ... and rheumatic changes can cause severe handicaps. ... the finger-joint prostheses was to produce a ... natural function as nearly possible.,The cementless RM ...
... hands play an important part in our ... and rheumatic changes can cause severe handicaps. ... the finger-joint prostheses was to produce a ... natural function as nearly possible.,The cementless RM ...
... precise control of the thigh during varus/valgus manipulation ... the proximal thigh during ACL or PCL procedures. ... on both right and left legs and may ... Holder can be used with an Arthrex tourniquet ...
... for trauma, foot and ankle or deformity ... External Fixation components are designed to reduce ... the complexity of intra-operative and post-operative frame ... and hinges eliminate the need to stock ...
Medicine Products: